Targeting the IL4 Receptor with MDNA55 in Patients with Recurrent Glioblastoma: Results of a Phase 2b Trial.

John H SampsonAchal Singh AchrolManish K AghiKrystof BankiewieczMartin BexonSteven BremAndrew BrennerChandtip ChandhasinSajeel ChowdharyMelissa CoelloBenjamin M EllingsonJohn R FloydSeunggu HanSantosh KesariYael MardorFahar MerchantNina MerchantDina RandazzoMichael VogelbaumFrank VrionisEva Wembacher-SchroederMiroslaw ZabekNicholas Butowski

Published in: Neuro-oncology (2023)

MDNA55 demonstrated tumor control and promising survival and may benefit rGBM patients when treated at high dose irrespective of IL4R expression level.

Keyphrases

high dose
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
poor prognosis
clinical trial
peritoneal dialysis
prognostic factors
low dose
study protocol
binding protein
randomized controlled trial
phase iii
drug delivery
open label
double blind